Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03275974 · ClinicalTrials.gov registry record · Phase 1
Glutamine PET Imaging Colorectal Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03275974: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03275974 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03275974, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The clinical trial studies how well 11C-glutamine and 18F-FSPG positron emission tomography (PET) imaging works in detecting tumors in patients with metastatic colorectal cancer compared to standard imaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scanning.
Interventions
- PROCEDURE Positron Emission Tomography
- PROCEDURE Blood Draw
- BIOLOGICAL Carbon C 11 Glutamine
- BIOLOGICAL Fluorine F 18 L-glutamate Derivative BAY94-9392
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-04-27 |
| Est. Completion | 2025-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03275974
The ClinicalTrials.gov registry entry for NCT03275974 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Positron Emission Tomography is the first listed.
NCT03275974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03275974 about?
NCT03275974 is a clinical study titled "Glutamine PET Imaging Colorectal Cancer". The clinical trial studies how well 11C-glutamine and 18F-FSPG positron emission tomography (PET) imaging works in detecting tumors in patients with metastatic colorectal cancer compared to standard imaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scanning.
What is the current status of trial NCT03275974?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-04-27. Estimated completion is 2025-12-23.
What interventions are being tested in trial NCT03275974?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Blood Draw (PROCEDURE), Carbon C 11 Glutamine (BIOLOGICAL), Fluorine F 18 L-glutamate Derivative BAY94-9392 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03275974?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.